环磷酰胺与利妥昔单抗诱导治疗ANCA相关血管炎的12个月死亡率比较:系统评价与荟萃分析
该系统评价与荟萃分析纳入48项研究,比较环磷酰胺与利妥昔单抗诱导治疗ANCA相关血管炎(AAV)的12个月死亡率。环磷酰胺组12个月死亡率为10.7%(95%CI 8.4-13.2),利妥昔单抗组为5.9%(95%CI 3.2-9.4),差异为4.8%(95%CI 0.5-9.0;p<0.001),支持利妥昔单抗。5项直接比较研究显示环磷酰胺死亡率降低1.34%(95%CI -6.5-3.7;p=0.59),无统计学显著性。
要点
- 利妥昔单抗诱导治疗AAV的12个月死亡率显著低于环磷酰胺(差异4.8%,95%CI 0.5-9.0)。
- 直接比较研究未显示两种诱导治疗间死亡率差异有统计学显著性(p=0.59)。
- 亚组敏感性分析仅GPA和治疗前BVAS<17亚组达到统计学显著性。
核心结论
- 总体分析显示利妥昔单抗诱导治疗AAV的12个月死亡率显著低于环磷酰胺(差异4.8%,95%CI 0.5-9.0;p<0.001)。
- 仅GPA和基线BVAS<17亚组的敏感性分析达到统计学显著性,仍需直接比较研究。
研究设计与样本
- 系统文献综述与荟萃分析,纳入48项评估环磷酰胺或利妥昔单抗诱导治疗后12个月死亡率的研究。
- 采用随机效应模型估计合并结果,使用I2统计量评估异质性,并进行敏感性分析。
主要发现
- 环磷酰胺组12个月总死亡率为10.7%(95%CI 8.4-13.2),利妥昔单抗组为5.9%(95%CI 3.2-9.4)。
- 两种诱导治疗12个月死亡率差异为4.8%(95%CI 0.5-9.0;p<0.001),支持利妥昔单抗。
- 5项直接比较研究显示环磷酰胺死亡率降低1.34%(95%CI -6.5-3.7;p=0.59),无统计学显著性。
- 基于治疗年份、性别和年龄的亚组敏感性分析显示利妥昔单抗组死亡率降低但无统计学显著性。
关键数值与推荐
- 环磷酰胺诱导治疗AAV的12个月死亡率为10.7%(95%CI 8.4-13.2)。
- 利妥昔单抗诱导治疗AAV的12个月死亡率为5.9%(95%CI 3.2-9.4)。
- 两种诱导治疗12个月死亡率差异为4.8%(95%CI 0.5-9.0;p<0.001),支持利妥昔单抗。
- 直接比较研究显示环磷酰胺死亡率降低1.34%(95%CI -6.5-3.7;p=0.59),无统计学显著性。
临床怎么用
- 在AAV诱导治疗选择时,可参考利妥昔单抗与环磷酰胺12个月死亡率差异支持利妥昔单抗的荟萃分析结果。
- 直接比较证据有限且无统计学显著性,临床决策需结合患者具体情况和直接研究证据。
局限性
- 直接比较环磷酰胺与利妥昔单抗诱导治疗的研究仅5项,证据有限。
- 亚组敏感性分析仅GPA和基线BVAS<17达到统计学显著性,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ANCA-associated vasculitis (AAV) survival rates have improved with advancement in therapeutics. The impact on mortality in AAV stratified by induction therapy is not known. AIM: To compare 12-month mortality in individuals with AAV who received cyclophosphamide versus rituximab induction therapy. METHODS: A systematic literature review was undertaken to identify studies assessing 12-month mortality after cyclophosphamide or rituximab for AAV induction therapy. A meta-analysis was conducted to estimate pooled results using a random effects model. The homogeneity of the study results was assessed using the I2 statistic and sensitivity analysis was undertaken to assess the impacts of study populations and study design on any statistical heterogeneity. RESULTS: 48 studies were included in the analysis. The overall mortality at 12 months for cyclophosphamide was 10.7% (95% CI 8.4-13.2) and rituximab was 5.9% (95% CI 3.2-9.4). The difference in 12-month mortality between induction therapies was 4.8% (95% CI 0.5-9.0; p < 0.001) favouring rituximab. Analysis from 5 studies that directly compared these treatments showed a small non-statistically significant reduction in mortality for cyclophosphamide (difference=1.34%, 95% CI -6.5-3.7; p = 0.59). Subgroup sensitivity analysis conducted based on year of treatment, sex and age, showed a reduced but not statistically significant mortality in the rituximab group. CONCLUSION: Overall, there was a statistically significant difference favouring rituximab in 12-month mortality rates after cyclophosphamide or rituximab induction treatment for AAV. Subgroup sensitivity analysis considering study populations consistently supported this result although only treatment for GPA and baseline BVAS <17 reached statistical significance. Further direct studies between cyclophosphamide and rituximab induction are required.
引用
- Allan C, Kaur G, Girgis L, et al. Cyclophosphamide vs rituximab induction therapy for ANCA-associated vasculitis. A systematic review and meta-analysis of 12-month mortality. Semin Arthritis Rheum. 2026. PMID: 42766981. doi:10.1016/j.semarthrit.2026.153078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。